创新药出海添变数？多家药企回应：BD战略不受影响

Core Viewpoint - The potential restrictions on Chinese innovative drugs entering the U.S. market have raised concerns, but many companies believe these rumors will not significantly impact their overseas expectations [1][3]. Industry Summary - Major U.S. pharmaceutical companies, including Pfizer and AstraZeneca, have shown a positive attitude towards acquiring Chinese innovative drugs, with Pfizer investing $6 billion in a dual-specific antibody from 3SBio [2]. - In 2024, China's pharmaceutical exports to the U.S. are projected to reach $19.047 billion, with a trade surplus of approximately $3.99 billion [2]. - In the first half of this year, the total value of Chinese innovative drug licensing out reached nearly $66 billion, surpassing the total for the entire year of 2024 [2]. - 38% of significant business development transactions in the U.S. this year involved Chinese drugs, a stark contrast to nearly zero in the previous decade [2]. Company Responses - Several domestic pharmaceutical companies, including Tigermed and Hualan Biological Engineering, have expressed that the recent market fluctuations are related to the rumors but do not foresee immediate impacts on their overseas strategies [3][4]. - Companies like Hualan Biological Engineering and BeiGene have indicated that their current operations remain stable, with ongoing clinical trials and business development plans unaffected by the rumors [5][6]. - The overall sentiment in the industry is one of cautious observation, with experts noting that the actual implementation of any restrictions remains uncertain [5][6].